Skip to main content
COVID-19 Notice: 

Diagnosis made simpler. Decisions made clear.

Macrilen™ is the first and only FDA-approved Adult Growth Hormone Deficiency (AGHD) oral diagnostic test available for in-office use.1

Diagnosis made simpler. Decisions made clear.

Macrilen™ is the first and only FDA-approved Adult Growth Hormone Deficiency (AGHD) oral diagnostic test available for in-office use.1

20-something white male with a happy expression is leaning against a giant glass of reconstituted Macrilen™ (macimorelin) 60 mg oral solution.

Model is for illustrative purposes only.

In-office administration

Macrilen™ (macimorelin) 60 mg icon illustrating a patient drinking a prepared oral solution

Prepare, dose, administer, and get results.

Co-pay assistance

Icon representing Macrilen™ (macimorelin) 60 mg co-pay assistance program

We can help with the cost of Macrilen™. Your eligible patients may pay as little as $75.a,b

aWith an annual co-pay assistance of up to $4425.
bThis is a one-time use offer. Enrollment in the co-pay program is subject to eligibility criteria and terms and conditions, and the enrollment timeframe is based on calendar year. Coverage is limited to co-pay or co-insurance for Macrilen™ product only and does not include deductible amounts or other office visits, procedures, or administration costs. Novo Nordisk has the right to charge, alter, or revoke eligibility criteria and terms and conditions at any time.

Selected Important Safety Information

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided

Indication and Limitation of Use

Macrilen™ (macimorelin) 60 mg for oral solution is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

  • The safety and diagnostic performance of Macrilen™ have not been established for subjects with a body mass index (BMI) >40 kg/m2

Important Safety Information cont’d

Warnings and Precautions

  • Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers with Macrilen™ can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration
  • Potential for False Negative Test Results in Recent Onset Hypothalamic Disease: Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation

Adverse Reactions

  • The most common adverse reactions are dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia

Please click here for Prescribing Information

FDA=Food and Drug Administration.

References

  1. Macrilen [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2019.